Summary
We have studied the pharmacokinetics of tenoxicam after single and multiple oral doses of 20 mg in five patients (2 men and 3 women) with end-stage renal disease undergoing haemodialysis.
After a single dose, tenoxicam had a half-life (t1/2) of 33 h, an apparent clearance (CL·f−1) of 4.3 ml·min−1, and an apparent volume of distribution (Vz·f−1) of 11.8 l. The maximum tenoxicam concentration (Cmax) was 4.3 mg·l−1 at a median tmax of 1.7 h. There were no significant differences between the values calculated from the pre- or post-dialyser port plasma samples.
Tenoxicam plasma concentrations measured during once daily dosing before and after haemodialysis showed that tenoxicam does not accumulate.
Our findings suggest that dosage adjustment may not be required in patients with end-stage renal disease on haemodialysis taking tenoxicam.
This is a preview of subscription content, log in via an institution to check access.
References
Kolle EU, Hengy H, Vollmer KO (1986) Pharmacokinetics of tenoxicam in man following oral administration. Arzneimittel Forsch Drug Res 33: 3–7
Horber FF, Guentert TW, Weidekamm E, Heizmann P, Descoeudres C, Frey FJ (1986) Pharmacokinetics of tenoxicam in patients with impaired renal function. Eur J Clin Pharmacol 29: 697–701
Crevoisier C, Heizmann P (1986) Pharmacokinetics of tenoxicam. Litera Rheumatol 5: 7–14
Bird HA, Allen JG, Dixon JS, Wright V (1985) A pharmacokinetic comparison of tenoxicam in plasma and synovial fluid. Br J Rheumatol 24: 351–356
Guentert TW, Heintz RC, Joly R (1987) Overview on the pharmacokinetics of tenoxicam. Eur J Rheumatol Inflamm 9: 15–25
Heizmann P, Korner J, Zinapold K (1986) Determination of tenoxicam in human plasma by high-performance liquid chromatography. J Chromatogr 374: 95–102
Daugirdas JT, Ing TS (eds) (1988) Handbook of dialysis. Little, Brown and Company, Boston, pp 520–521
Simon P, Meyrier A, Brissot P (1981) Uremia and the liver. II. Drugs and the liver in the uremic patient. Nephron 29: 7–13
Todd PA, Clissold SP (1991) Tenoxicam. An update of its pharmacology and therapeutic efficacy in rheumatic disease. Drugs 41: 625–646
Ichihara S, Tsuyuki Y, Tomisawa H, Fukazawa H, Nakayama N, Tateishi M, Joly R (1984) Metabolism of tenoxicam in rats. Xenobiotica 14: 727–739
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Al-Ghamdi, M.S., Al-Mohanna, F.A., Al-Mustafa, Z.H. et al. The effect of haemodialysis on the pharmacokinetics of tenoxicam in patients with end-stage renal disease. Eur J Clin Pharmacol 43, 197–199 (1992). https://doi.org/10.1007/BF01740671
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01740671